Department of Internal Medicine, Virginia Mason Medical Center, Seattle, WA, USA.
J Clin Gastroenterol. 2010 Jan;44(1):46-51. doi: 10.1097/01.mcg.0000360462.64261.55.
To clinically evaluate the patients with hereditary pancreatitis (HP) before the first, after the first and last interventional endoscopic retrograde cholangiopancreatography (ERCP), and at follow-up.
There are limited data evaluating the outcomes and role of interventional ERCP in HP.
Between 1990 and 2008, 21 consecutive patients with HP were retrospectively assessed for response to therapeutic ERCP. Medical records were reviewed and a telephone survey was conducted to obtain information.
Patients underwent a total of 87 interventional ERCPs (mean 4, range: 1 to 11) and were followed-up for a mean period of 5 years (2 to 212 mo) from the last ERCP. The mean age at diagnosis, first ERCP, and follow-up was 15, 19, and 27 years (2 to 39 y), respectively. Eleven of 12 patients (92%) who received surgical therapy required subsequent interventional ERCPs. Before and after first ERCP mean pain scores decreased from 8.3 to 3.2 (P=0.001) and after last ERCP scores decreased to 2.7 (P=0.001). Yearly hospital visits including urgent care and emergency room visits decreased from 5.7 to 1.9 (P<0.001) and then to 1.6 (P=0.001). Daily oxycodone equivalent usage decreased from 39 to 34 mg (P=0.7) and then to 9.4 mg (P=0.05). Complications included pancreatitis in 3% with no perforations, bleeding, or infection.
Despite decompressive or resective surgeries in 12 of 21 patients, the majority (92%) developed subsequent complications and required endoscopic therapy. Endoscopic management for amenable lesions often requires multiple ERCPs. Interventional ERCPs in patients with HP is associated with decreased pain, analgesic usage, hospitalizations, and episodes of recurrent pancreatitis.
在首次、首次后和最后一次经内镜逆行胰胆管造影(ERCP)前以及随访时对遗传性胰腺炎(HP)患者进行临床评估。
评估 HP 患者接受介入性 ERCP 的结果和作用的数据有限。
在 1990 年至 2008 年间,回顾性评估了 21 例连续 HP 患者对治疗性 ERCP 的反应。查阅病历并进行电话调查以获取信息。
患者共接受了 87 次介入性 ERCP(平均 4 次,范围:1 至 11 次),并在最后一次 ERCP 后平均随访 5 年(2 至 212 个月)。诊断时、首次 ERCP 和随访时的平均年龄分别为 15 岁、19 岁和 27 岁(2 至 39 岁)。12 例接受手术治疗的患者中有 11 例(92%)需要后续介入性 ERCP。首次 ERCP 前后平均疼痛评分从 8.3 降至 3.2(P=0.001),末次 ERCP 后降至 2.7(P=0.001)。包括急诊就诊在内的每年住院就诊次数从 5.7 次减少到 1.9 次(P<0.001),然后减少到 1.6 次(P=0.001)。每日羟考酮等效剂量从 39 毫克减少到 34 毫克(P=0.7),然后减少到 9.4 毫克(P=0.05)。并发症包括 3%的胰腺炎,无穿孔、出血或感染。
尽管 21 例患者中有 12 例行减压或切除术,但大多数(92%)出现后续并发症并需要内镜治疗。对可治疗病变的内镜治疗通常需要多次 ERCP。HP 患者的介入性 ERCP 可降低疼痛、镇痛药使用、住院和复发性胰腺炎的发作。